CoChat
Sign Up
Cited by 11Genomics and Rare DiseasesPrenatal Screening and DiagnosticsHemoglobinopathies and Related Disorders

The DOI matches its Crossref record; the references it cites are not checked yet.

Targeted long-read sequencing facilitates effective carrier screening for complex monogenic diseases including spinal muscular atrophy, α-/β-thalassemia, 21-hydroxylase deficiency, and fragile-X syndrome

Open access
Li, Shuyuan, Hua, Renyi, Han, Xu, Xu, Yan, Li, Ming, Gao, Li, Ma, Ruiyu, Meng, Wanli, Mao, Aiping, Wang, Jian, Wang, Yanlin·2025·Journal of Translational Medicine
DOI 10.1186/s12967-025-06345-1PMC PMC11895162
Open this paper in CoChat — free account

Abstract

BACKGROUND: Next-generation sequencing (NGS) has been applied for carrier screening, effectively reducing the incidence of severe diseases. However, some severe, high-prevalent and complex diseases, including spinal muscular atrophy (SMA), α-/β-thalassemia, 21-hydroxylase deficiency (21-OHD), and fragile-X syndrome (FXS), cannot be fully addressed by NGS, resulting in a high residual risk ratio. This study aims to evaluate the clinical utility of a long-read sequencing (LRS) panel for carrier screening of these five complex diseases. METHODS: A total of 2926 participants were retrospectively enrolled from International Peace Maternity and Child Health Hospital from Jan 2019 to Dec 2022. All the participants were previously screened for 149 genes correlated to 147 diseases by NGS. The samples were collected and analyzed with the LRS panel targeting the five complex diseases. RESULTS: LRS identified 236 carrier variants, including 54 for SMA, 113 for α-thalassemia, 19 for β-thalassemia, 47 for 21-OHD, and three for FXS. NGS identified only 56.4% (133/236) of the variants detected by LRS. NGS failed to detect three SMA carriers with SMN1 intragenic variants, while reported 10 false-positive carriers for α-thalassemia (HKαα miscalled as -α3.7). Both 21-OHD and FXS were beyond its detection scope. NGS identified only three of the seven at-risk couples determined by LRS. The total estimated at-risk couple rate for 151 genes in NGS and LRS panels was 1.0996%. SMA, α-/β-thalassemia, 21-OHD, and FXS were among the top 30 high-prevalent diseases and had a combined at-risk couple rate of 0.2433%, accounting for 22.1% of the total ratio. NGS could only identify 22.7% of the at-risk couples for the five diseases in the LRS panel. CONCLUSIONS: Comprehensive carrier screening for high-prevalent diseases had higher clinical utility than expanding the list of low-prevalent diseases. Incorporating LRS into the NGS carrier screening strategy would facilitate more effective carrier screening.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12967-025-06345-1

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists haven’t been fetched yet

References 40 · Cited by 11

Research works printed but not linked: 38

  1. Gregg AR, Aarabi M, Klugman S, Leach NT, Bashford MT, Goldwaser T, Chen E, Sparks TN, Reddi HV, Rajkovic A, Dungan JS. Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23:1793–806. · DOI · Paper page
  2. Westemeyer M, Saucier J, Wallace J, Prins SA, Shetty A, Malhotra M, Demko ZP, Eng CM, Weckstein L, Boostanfar R, et al. Clinical experience with carrier screening in a general population: support for a comprehensive pan-ethnic approach. Genet Med. 2020;22:1320–8. · DOI
  3. Haque IS, Lazarin GA, Kang HP, Evans EA, Goldberg JD, Wapner RJ. Modeled fetal risk of genetic diseases identified by expanded carrier screening. JAMA. 2016;316:734–42. · DOI
  4. Guo MH, Gregg AR. Estimating yields of prenatal carrier screening and implications for design of expanded carrier screening panels. Genet Med. 2019;21:1940–7. · DOI
  5. Beauchamp KA, Johansen Taber KA, Muzzey D. Clinical impact and cost-effectiveness of a 176-condition expanded carrier screen. Genet Med. 2019;21:1948–57. · DOI
  6. Zhao S, Xiang J, Fan C, Asan, Shang X, Zhang X, Chen Y, Zhu B, Cai W, Chen S, et al. Pilot study of expanded carrier screening for 11 recessive diseases in China: results from 10,476 ethnically diverse couples. Eur J Hum Genet. 2019;27:254–62. · DOI
  7. Zhang X, Chen Q, Li J, Luo X, Luo J, Li J, Zeng Z, Wu Y, Zhang H, Dong Y. The effectiveness of expanded carrier screening based on next-generation sequencing for severe monogenic genetic diseases. Hum Genomics. 2024;18:9. · DOI
  8. Beauchamp KA, Muzzey D, Wong KK, Hogan GJ, Karimi K, Candille SI, Mehta N, Mar-Heyming R, Kaseniit KE, Kang HP, et al. Systematic design and comparison of expanded carrier screening panels. Genet Med. 2018;20:55–63. · DOI
  9. Punj S, Akkari Y, Huang J, Yang F, Creason A, Pak C, Potter A, Dorschner MO, Nickerson DA, Robertson PD, et al. Preconception carrier screening by genome sequencing: results from the clinical laboratory. Am J Hum Genet. 2018;102:1078–89. · DOI
  10. Feng Y, Ge X, Meng L, Scull J, Li J, Tian X, Zhang T, Jin W, Cheng H, Wang X, et al. The next generation of population-based spinal muscular atrophy carrier screening: comprehensive pan-ethnic SMN1 copy-number and sequence variant analysis by massively parallel sequencing. Genet Med. 2017;19:936–44. · DOI
  11. Zhao S, Wang W, Wang Y, Han R, Fan C, Ni P, Guo F, Zeng F, Yang Q, Yang Y, et al. NGS-based spinal muscular atrophy carrier screening of 10,585 diverse couples in China: a pan-ethnic study. Eur J Hum Genet. 2021;29:194–204. · DOI
  12. He J, Song W, Yang J, Lu S, Yuan Y, Guo J, Zhang J, Ye K, Yang F, Long F, et al. Next-generation sequencing improves thalassemia carrier screening among premarital adults in a high prevalence population: the Dai nationality, China. Genet Med. 2017;19:1022–31. · DOI
  13. Huang R, Liu Y, Xu J, Lin D, Mao A, Yang L, Zhong G, Wang H, Xu R, Chen Y, Zhou Q. Back-to-back comparison of third-generation sequencing and next-generation sequencing in carrier screening of Thalassemia. Arch Pathol Lab Med. 2023;148:797. · DOI
  14. Gangodkar P, Khadilkar V, Raghupathy P, Kumar R, Dayal AA, Dayal D, Ayyavoo A, Godbole T, Jahagirdar R, Bhat K, et al. Clinical application of a novel next generation sequencing assay for CYP21A2 gene in 310 cases of 21- hydroxylase congenital adrenal hyperplasia from India. Endocrine. 2021;71:189–98. · DOI
  15. Wang W, Han R, Yang Z, Zheng S, Li H, Wan Z, Qi Y, Sun S, Ye L, Ning G. Targeted gene panel sequencing for molecular diagnosis of congenital adrenal hyperplasia. J Steroid Biochem Mol Biol. 2021;211: 105899. · DOI · Paper page
  16. Bahlo M, Bennett MF, Degorski P, Tankard RM, Delatycki MB, Lockhart PJ. Recent advances in the detection of repeat expansions with short-read next-generation sequencing. F1000Res. 2018;7:736. · DOI · Paper page
  17. Oehler JB, Wright H, Stark Z, Mallett AJ, Schmitz U. The application of long-read sequencing in clinical settings. Hum Genomics. 2023;17:73. · DOI
  18. Li S, Han X, Xu Y, Chang C, Gao L, Li J, Lu Y, Mao A, Wang Y. Comprehensive analysis of spinal muscular atrophy: SMN1 copy number, intragenic mutation, and 2 + 0 carrier analysis by third-generation sequencing. J Mol Diagn. 2022;24:1009–20. · DOI
  19. Li S, Han X, Zhang L, Xu Y, Chang C, Gao L, Zhan J, Hua R, Mao A, Wang Y. An effective and universal long-read sequencing-based approach for SMN1 2 + 0 carrier screening through family trio analysis. Clin Chem. 2023;69:1295–306. · DOI
  20. Liang Q, Gu W, Chen P, Li Y, Liu Y, Tian M, Zhou Q, Qi H, Zhang Y, He J, et al. A more universal approach to comprehensive analysis of thalassemia alleles (CATSA). J Mol Diagn. 2021;23:1195–204. · DOI
  21. Huang W, Qu S, Qin Q, Yang X, Han W, Lai Y, Chen J, Zhou S, Yang X, Zhou W. Nanopore third-generation sequencing for comprehensive analysis of hemoglobinopathy variants. Clin Chem. 2023;69:1062–71. · DOI
  22. Liu Y, Chen M, Liu J, Mao A, Teng Y, Yan H, Zhu H, Li Z, Liang D, Wu L. Comprehensive analysis of congenital adrenal hyperplasia using long-read sequencing. Clin Chem. 2022;68:927–39. · DOI · Paper page
  23. Tantirukdham N, Sahakitrungruang T, Chaisiwamongkol R, Pongpanich M, Srichomthong C, Assawapitaksakul A, Buasong A, Tongkobpetch S, Yeetong P, Shotelersuk V. Long-read amplicon sequencing of the CYP21A2 in 48 Thai patients with steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab. 2022;107:1939–47. · DOI
  24. Liang Q, Liu Y, Liu Y, Duan R, Meng W, Zhan J, Xia J, Mao A, Liang D, Wu L. Comprehensive analysis of fragile X syndrome: full characterization of the FMR1 locus by long-read sequencing. Clin Chem. 2022;68:1529–40. · DOI
  25. Hou F, Mao A, Shan S, Li Y, Meng W, Zhan J, Nie W, Jin H. Evaluating the clinical utility of a long-read sequencing-based approach in genetic testing of fragile-X syndrome. Clin Chim Acta. 2023;551: 117614. · DOI
  26. Bai J, Qu Y, Huang W, Meng W, Zhan J, Wang H, Hou W, Jin Y, Mao A, Song F. A high-fidelity long-read sequencing-based approach enables accurate and effective genetic diagnosis of spinal muscular atrophy. Clin Chim Acta. 2024;553: 117743. · DOI
  27. Liang Q, He J, Li Q, Zhou Y, Liu Y, Li Y, Tang L, Huang S, Li R, Zeng F, et al. Evaluating the clinical utility of a long-read sequencing-based approach in prenatal diagnosis of Thalassemia. Clin Chem. 2023;69:239–50. · DOI
  28. Yuan D, Cai R, Mao A, Tan J, Zhong Q, Zeng D, Tang N, Wei X, Huang J, Zhang Y, et al. Improved genetic characterization of congenital adrenal hyperplasia by long-read sequencing compared with multiplex ligation-dependent probe amplification plus sanger sequencing. J Mol Diagn. 2024;26:770. · DOI · Paper page
  29. Zhang R, Cui D, Song C, Ma X, Cai N, Zhang Y, Feng M, Cao Y, Chen L, Qiang R. Evaluating the efficacy of a long-read sequencing-based approach in the clinical diagnosis of neonatal congenital adrenocortical hyperplasia. Clin Chim Acta. 2024;555: 117820. · DOI
  30. Chen T, Fan C, Huang Y, Feng J, Zhang Y, Miao J, Wang X, Li Y, Huang C, Jin W, et al. Genomic sequencing as a first-tier screening test and outcomes of newborn screening. JAMA Netw Open. 2023;6: e2331162. · DOI
  31. Zhu Y, Hu L, Yang L, Wang L, Lu Y, Dong X, Xiao T, Xu Z, Wu B, Zhou W. Association between expanded genomic sequencing combined with hearing screening and detection of hearing loss among newborns in a neonatal intensive care unit. JAMA Netw Open. 2022;5: e2220986. · DOI
  32. Baumgartner-Parzer S, Witsch-Baumgartner M, Hoeppner W. EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency. Eur J Hum Genet. 2020;28:1341–67. · DOI · Paper page
  33. Auer MK, Nordenström A, Lajic S, Reisch N. Congenital adrenal hyperplasia. Lancet. 2023;401:227–44. · DOI
  34. Bonello-Palot N, Benoit A, Agouti I, Hamouda I, Brousse V, Badens C. Transfusion requirements and complication rate in β-thalassemia intermedia due to heterozygous β-globin gene mutation and triplicated α-globin genes. Eur J Haematol. 2023;111:742–7. · DOI
  35. Spector E, Behlmann A, Kronquist K, Rose NC, Lyon E, Reddi HV. Laboratory testing for fragile X, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021;23:799–812. · DOI
  36. Liu Y, Li D, Yu D, Liang Q, Chen G, Li F, Gao L, Li Z, Xie T, Wu L, et al. Comprehensive analysis of hemophilia A (CAHEA): towards full characterization of the f8 gene variants by long-read sequencing. Thromb Haemost. 2023;123:1151–64. · DOI
  37. Reiner J, Rosenblum LS, Xin W, Zhou Z, Zhu H, Leach N. Incidental molecular diagnoses and heterozygous risk alleles in a carrier screening cohort. Genet Med. 2023;25: 100317. · DOI
  38. Guo Q, Chang YY, Huang CH, Hsiao YS, Hsiao YC, Chiu IF, Zhou Y, Zhang H, Ko TM. Population-based carrier screening and prenatal diagnosis of fragile X syndrome in East Asian populations. J Genet Genomics. 2021;48:1104–10. · DOI

Metadata

Authors
Li, S., Hua, R., Han, X., Xu, Y., Li, M., Gao, L., Ma, R., Meng, W., Mao, A., Wang, J., & Wang, Y.
Affiliations
Shanghai Jiao Tong University (CN)
Corresponding author
  • Mao, Aiping
  • Wang, Jian
  • Wang, Yanlin
ORCID
Venue
Journal of Translational Medicine
Publisher
Springer Science and Business Media LLC
Published
2025-03-11
Volume
23
Issue
1
Pages
307-307
ISSN
1479-5876 (ISSN-L)
DOI
10.1186/s12967-025-06345-1
PMC
PMC11895162
OpenAlex
W4408327485
Cited by
11
References
40
Citations by year
2026: 7 · 2025: 4
FWCI
6.47
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Translational Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • the Shanghai Municipal Science and Technology Commission (22Y11902300, 22Y11906700)
  • Clinical Research Plan of IPMCH (IPMCH2022CR1-02)
  • the National Natural Science Foundation of China (81971401, 81871136)
  • the National Key Technology Research and Development Program of the Ministry of Science and Technology (2023YFC2705901)
  • the Shanghai Municipal Key Clinical Specialty
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Screening and Diagnostics
  • Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
Keywords
carrier screening, long-read sequencing, spinal muscular atrophy, alpha-thalassemia, beta-thalassemia, 21-hydroxylase deficiency, fragile X syndrome, monogenic disorders, residual risk, gene panel, prenatal diagnosis
MeSH terms
Adrenal Hyperplasia, Congenital, Adult, Female, Fragile X Syndrome, Genetic Testing, Heterozygote, Genetic Carrier Screening, Humans, Male, Muscular Atrophy, Spinal, alpha-Thalassemia, beta-Thalassemia, High-Throughput Nucleotide Sequencing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review